Shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) traded up 1.9% during mid-day trading on Monday . The stock traded as high as $11.25 and last traded at $11.06, with a volume of 165,392 shares trading hands. The stock had previously closed at $10.85.

Several analysts have issued reports on the company. Zacks Investment Research upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, April 26th. JMP Securities restated a “buy” rating and set a $67.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, June 16th. Royal Bank Of Canada cut Esperion Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $30.00 to $15.00 in a research report on Wednesday, June 29th. JPMorgan Chase & Co. cut Esperion Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $50.00 to $15.00 in a research report on Wednesday, June 29th. Finally, Barclays PLC cut Esperion Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $28.00 to $13.00 in a research report on Wednesday, June 29th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Esperion Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $24.40.

The stock’s market capitalization is $252.11 million. The stock’s 50-day moving average price is $10.92 and its 200 day moving average price is $14.93.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.16. During the same period last year, the company earned ($0.55) EPS. On average, equities research analysts predict that Esperion Therapeutics Inc. will post ($3.36) earnings per share for the current year.

In other news, Director Mark E. Mcgovern bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 6th. The shares were acquired at an average cost of $10.00 per share, with a total value of $50,000.00. Following the completion of the transaction, the director now directly owns 600 shares in the company, valued at $6,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.